Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality: A Randomized Placebo Controlled Clinical Trial
The trial employs a two-armed parallel placebo controlled trial design whereby patients with
a diagnosis of non small cell lung cancer are randomized to receive either 20 mg of
melatonin nightly or an identically matched placebo. All patients will be followed for two
years with primary outcomes assessed at a two year time point and secondary outcomes
evaluated throughout the course of the trial.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Lung Cancer Recurrence or mortality
2 years
No
Dugald MR Seely, ND, MSc
Principal Investigator
The Canadian College of Naturopathic Medicine
Canada: Health Canada
2007077-01H
NCT00668707
September 2007
March 2017
Name | Location |
---|